Abstract：Objective To analyze the trend in the mortality of liver cancer in Ningbo City from 2002 to 2021, so as to provide the evidence for improving the liver cancer control measures. Methods The liver cancer mortality data in Ningbo City from 2002 to 2021 were collected from Ningbo Municipal Chronic Disease Surveillance System. The crude mortality and standardized mortality by the 2 000 national population census data of liver cancer were estimated, and the proportion of concomitant diseases was analyzed among all dead patients with liver cancer. In addition, the trends in liver cancer mortality were analyzed with annual percentage change (APC) and average annual percentage change (AAPC). Results Both the crude and standardized mortality of liver cancer appeared a tendency towards a decline year by year in Ningbo City from 2002 to 2021, with AAPC of -3.47% (95%CI: -4.08% to -2.85%, P<0.001) and -6.56% (95%CI: -7.25% to -5.87%, P<0.001), and a the decline in liver cancer mortality was larger during the period between 2006 and 2021 than during the period between 2002 and 2006. The annual mean crude and standardized mortality of liver cancer was 35.39/105 and 20.98/105, and the crude mortality of liver cancer was 52.69/105 in men and 18.13/105 in women, respectively. After adjustment for age, the risk of liver cancer mortality was 3.03 (95%CI: 2.96-3.09) times greater among men than among women, and the mortality of liver cancer appeared a tendency towards a rise with age (χ2trend=45 684.254, P<0.001). Concomitant diseases were found among 9 985 dead cases with liver cancer (24.44%), and the concomitant diseases mainly included digestive system diseases (predominantly liver diseases) and infectious and parasitic diseases (predominantly virus hepatitis). Conclusions The mortality of liver cancer appeared a tendency towards a decline in Ningbo City from 2002 to 2021, and men and middle-aged and elderly residents were at high risk of liver cancer mortality. Digestive system diseases and infectious and parasitic diseases were predominant concomitant diseases among dead patients with liver cancer.
应焱燕, 王永, 陈洁平, 李思萱, 包凯芳, 王思嘉, 许国章. 2002—2021年宁波市肝癌死亡趋势分析[J]. 预防医学, 2022, 34(12): 1218-1223.
YING Yanyan, WANG Yong, CHEN Jieping, LI Sixuan, BAO Kaifang, WANG Sijia, XU Guozhang. Trend in mortality of liver cancer in Ningbo City from 2002 to 2021. Preventive Medicine, 2022, 34(12): 1218-1223.
[1] SUNG H,FERLAY J,SIEGEL R L,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249. [2] 刘宗超,李哲轩,张阳,等.2020全球癌症统计报告解读[J].肿瘤综合治疗电子杂志,2021,7(2):1-14. LIU Z C,LI Z X,ZHANG Y,et al.Interpretation on the report of Global Cancer Statistics 2020[J].J Multidiscipl Cancer Manag(Electron Version),2021,7(2):1-14. [3] BERTUCCIO P,TURATI F,CARIOLI G,et al.Global trends and predictions in hepatocellular carcinoma mortality[J].J Hepatol,2017,67(2):302-309. [4] 贺君剑,魏长慧,李众,等.中国居民2004—2016年肝癌死亡趋势分析[J].郑州大学学报(医学版),2020,55(1):119-122. HE J J,WEI C H,LI Z,et al.Analysis of liver cancer mortality trend among Chinese residents from 2004 to 2016[J].J Zhengzhou Univ(Med Sci),2020,55(1):119-122. [5] 李莉,宋凯,杜灵彬,等.2000—2009年浙江省肿瘤登记地区肝癌发病和死亡情况分析[J].中华预防医学杂志,2014,48(7):634-637. LI L,SONG K,DU L B,et al.Analysis on incidence and death of liver cancer in Zhejiang Cancer Registration Areas from 2000 to 2009[J].Chin J Prev Med,2014,48(7):634-637. [6] 沈飞琼,杨金华,李其龙,等.2010—2014年浙江省肿瘤登记地区肝癌发病与死亡分析[J].中国肿瘤,2019,28(10):764-768. SHEN F Q,YANG J H,LI Q L,et al.Incidence and mortality of liver cancer in Zhejiang Cancer Registration Areas from 2010 to 2014[J].China Cancer,2019,28(10):764-768. [7] 王浩,胡如英,张新卫.浙江省肝癌死亡率地理特征分析[J].浙江预防医学,2009,21(11):1-2,5. WANG H,HU R Y,ZHANG X W.Trend-surface analysis of geographical distribution of liver cancer mortality in Zhejiang Province[J].Zhejiang J Prev Med,2009,21(11):1-2,5. [8] 北京协和医院世界卫生组织疾病分类合作中心.疾病和有关健康问题的国际统计分类第十次修订本第二卷[M].北京:人民卫生出版社,1997. [9] 周犇,张宁,徐晓燕.常熟市居民肝癌死亡趋势分析[J].江苏预防医学,2014,25(1):53-55. ZHOU B,ZHANG N,XU X Y.Trends in mortality of liver cancer in Changshu City[J].Jiangsu J Prev Med,2014,25(1):53-55. [10] 姜永晓,马臣,全培良,等.河南省居民1984—2009年肝癌死亡率趋势分析及预测[J].肿瘤,2012,32(7):522-525. JIANG Y X,MA C,QUAN P L,et al.Time trend analysis and prediction of liver cancer mortality of residents in Henan Province,1984-2009[J].Tumor,2012,32(7):522-525. [11] 杨帆,曹毛毛,李贺,等.1990—2019年中国人群肝癌流行病学趋势分析及预测[J].中华消化外科杂志,2022,21(1):106-113. YANG F,CAO M M,LI H,et al.Analysis and prediction of the epidemiological trend of liver cancer in the Chinese population from 1990 to 2019[J].Chin J Dig Surg,2022,21(1):106-113. [12] 柴文杰,王良友,乔冬菊,等.2010—2016年台州市居民肝癌发病和死亡趋势分析[J].预防医学,2019,31(9):933-935,939. CHAI W J,WANG L Y,QIAO D J,et al.Tendency analysis of incidence and mortality of hepatocellular carcinoma in Taizhou residents from 2010 to 2016[J].Prev Med,2019,31(9):933-935,939. [13] 亓文婷. 山东省乙型肝炎、肝硬化、肝癌的流行趋势和疾病负担分析[D].济南:山东大学,2010. QI W T.The epidemiological trend and the burden of diseases of hepatitis B,liver cirrhosis and liver cancer in Shandong Province of China[D].Jinan:Shandong University,2010. [14] 董航,陈远源,李科,等.2010—2019年广州市肝癌死亡情况与趋势分析[J].实用预防医学,2021,28(11):1315-1318. DONG H,CHEN Y Y,LI K,et al.Mortality and trends of liver cancer in Guangzhou City,2010-2019[J].Pract Prev Med,2021,28(11):1315-1318. [15] 焦娇,郭意男,章国君,等.乙肝肝硬化进展原发性肝癌的危险因素研究[J].预防医学,2019,31(4):363-367. JIAO J,GUO Y N,ZHANG G J,et al.Advance in research of risk factors for hepatitis B cirrhosis progressing to primary hepatic carcinoma[J].Prev Med,2019,31(4):363-367. [16] 李婷,时代强.HBV感染型原发性肝癌肿瘤微环境T淋巴细胞亚群的表达[J].预防医学,2018,30(4):387-388. LI T,SHI D Q.Expression of T lymphocyte subsets in tumor microenvironment of HBV infected primary liver cancer[J].Prev Med,2018,30(4):387-388. [17] POON D,ANDERSON B O,CHEN L T,et al.Management of hepatocellular carcinoma in Asia:consensus statement from the Asian Oncology Summit 2009[J].Lancet Oncol,2009,10(11):1111-1118. [18] 朱银潮,许国章,张涛,等.浙江省宁波市市民健康相关行为现状[J].中国健康教育,2010,26(8):622-623,629. ZHU Y C,XU G Z,ZHANG T,et al.Status of health related behaviors among residents in Ningbo City,Zhejiang Province[J].Chin J Health Educ,2010,26(8):622-623,629. [19] 曾红梅,曹毛毛,郑荣寿,等.2000—2014年中国肿瘤登记地区肝癌发病年龄变化趋势分析[J].中华预防医学杂志,2018,52(6):573-578. ZENG H M,CAO M M,ZHENG R S,et al.Trend analysis of age of diagnosis for liver cancer in cancer registry areas of China,2000-2014[J].Chin J Prev Med,2018,52(6):573-578. [20] 郑荣寿,左婷婷,曾红梅,等.中国肝癌死亡状况与生存分析[J].中华肿瘤杂志,2015,37(9):697-702. ZHENG R S,ZUO T T,ZENG H M,et al.Mortality and survival analysis of liver cancer in China[J].Chin J Oncol,2015,37(9):697-702. [21] 夏毅,宋桂香,舒宝刚,等.上海市一九九二年死亡资料多死因分析[J].中国社会医学,1994(3):42-47,51. XIA Y,SONG G X,SHU B G,et al.Mutireason of death analysis on death data of Shanghai in1992[J].Chin J Soc Med,1994(3):42-47,51. [22] 周泽文,刘颖春,向邦德,等.原发性肝癌的全球展望:流行情况、危险因素和人群归因分值[J].中国癌症防治杂志,2021,13(1):14-21. ZHOU Z W,LIU Y C,XIANG B D,et al.Global outlook for primary liver cancer:prevalence,risk factors,and population attribution scores[J].Chin J Oncol Prev Treat,2021,13(1):14-21. [23] 揭彬,白春花,毕华强,等.乙肝患者肝癌诊断前规范筛查的影响因素分析[J].预防医学,2021,33(5):433-437. JIE B,BAI C H,BI H Q,et al.Factors associated with adherence to screening before diagnosis of hepatocellular carcinoma related to chronic hepatitis B[J].Prev Med,2021,33(5):433-437.
